Featured Content
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Daratumumab-Based Triplet Therapy Shows Benefits for Relapsed/Refractory Multiple Myeloma
Source: Myeloma - Hematology Advisor Researchers sought to determine whether there were benefits with early use of daratumumab-based triplet therapies in patients with relapsed/refractory multiple myeloma. Read More
Daratumumab May Improve Bone Metabolism in Relapsed/Refractory Multiple Myeloma
Source: Myeloma - Hematology Advisor Researchers sought to determine whether treatment with daratumumab may be associated with trends of improved bone turnover. Read More
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
Source: Myeloma : nature.com subject feeds Post Content Read More
A-Fib Linked to Worse Hospital Outcomes in Multiple Myeloma
Source: Myeloma - Hematology Advisor In stratified analysis, odds of all-cause mortality, hospital stay of more than five days higher for MM patients not using anticoagulation. Read More
Calorie restriction has no effect on bone marrow tumour burden in a Vk*MYC transplant model of multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Outcomes for Bacterial Meningitis in Patients With Multiple Myeloma
Source: Myeloma - Hematology Advisor Researchers sought to determine the outcomes for patients with multiple myeloma who develop bacterial meningitis. Read More
Measuring Circulating Tumor Cells at Diagnosis Can Improve Risk Stratification in Multiple Myeloma
Source: Myeloma - Hematology Advisor Circulating tumor cell levels were an independent predictor of progression-free survival and overall survival. Read More
Exploiting gene dependency to inform drug development for multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Immune senescence in multiple myeloma—a role for mitochondrial dysfunction?
Source: Myeloma : nature.com subject feeds Post Content Read More
Ocular Toxicity Appears Common With Belantamab Mafodotin in Advanced Multiple Myeloma
Source: Myeloma - Hematology Advisor Researchers sought to determine whether ocular toxicity occurred in a significant number of patients with multiple myeloma treated with belantamab mafodotin. Read More
Recent Publications
Blood Cancer and the Heart: Light Chain Cardiomyopathy in Refractory Multiple Myeloma
Case Rep Cardiol. 2022 Jul 30;2022:7846846. doi: 10.1155/2022/7846846. eCollection 2022. ABSTRACT We report a case of a 57-year-old woman with a history of multiple myeloma (MM) and light chain (AL) amyloidosis who presented due to worsening dyspnea on exertion. Her...
Deepening Responses Post Upfront ASCT in Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
Transplant Cell Ther. 2022 Aug 5:S2666-6367(22)01519-6. doi: 10.1016/j.jtct.2022.07.030. Online ahead of print. ABSTRACT BACKGROUND: High dose melphalan followed by autologous stem cell transplant (ASCT) remains the standard of care for transplant-eligible patients...
Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma
Transplant Cell Ther. 2022 Aug 5:S2666-6367(22)01515-9. doi: 10.1016/j.jtct.2022.07.028. Online ahead of print. ABSTRACT BACKGROUND: Maintenance therapy with single-agent lenalidomide (Len) after autologous hematopoietic stem cell transplantation (autoHCT) for...
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
Blood Adv. 2022 Aug 8:bloodadvances.2022008320. doi: 10.1182/bloodadvances.2022008320. Online ahead of print. ABSTRACT Idecabtagene vicleucel (ide-cel) was FDA approved in March 2021 for the treatment of relapsed/refractory multiple myeloma (RRMM) after 4 lines of...
Circulating miR-448 acts as a potential diagnostic biomarker for multiple myeloma
Hematology. 2022 Dec;27(1):847-852. doi: 10.1080/16078454.2022.2106818. ABSTRACT OBJECTIVE: The current diagnostic methods for multiple myeloma (MM) include bone marrow aspiration and biopsy, which are not only complicated but also invasive, causing great pain to...
Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed Hyperleukocytic Acute Myeloma Leukemia
Contrast Media Mol Imaging. 2022 Jul 13;2022:7828230. doi: 10.1155/2022/7828230. eCollection 2022. ABSTRACT PURPOSE: To explore whether and why abnormal coagulation function and hemorrhage can appear in patients with hyperleukocytic acute myeloid leukemia (HAML)....
Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis
Hemasphere. 2022 Aug 2;6(8):e758. doi: 10.1097/HS9.0000000000000758. eCollection 2022 Aug. NO ABSTRACT PMID:35935609 | PMC:PMC9348860 | DOI:10.1097/HS9.0000000000000758
Prognostic Stratification of Multiple Myeloma Using Clinicogenomic Models: Validation and Performance Analysis of the IAC-50 Model
Hemasphere. 2022 Aug 2;6(8):e760. doi: 10.1097/HS9.0000000000000760. eCollection 2022 Aug. ABSTRACT A growing need to evaluate risk-adapted treatments in multiple myeloma (MM) exists. Several clinical and molecular scores have been developed in the last decades, which...
